Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

May 14, 2021

Study Completion Date

September 1, 2021

Conditions
COVID19 ARDS
Interventions
BIOLOGICAL

Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells

"Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.~day 0: 1.10\^6 MSC/kg day 3: 0.5. 10\^6 MSC/kg day 5: 0.5 . 10\^6 MSC/kg"

BIOLOGICAL

Placebo

Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day).

Trial Locations (1)

54500

Nancy University Hospital, Vandœuvre-lès-Nancy

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER

NCT04625738 - Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome | Biotech Hunter | Biotech Hunter